File: '\\swfile\EmailIn\20240426 131447 Attachment 240426 BHSC NR RSU and Warrant issuance Final.docx'

CSE:BHSC - FSE:8MV - OTC: CNVCF OFSE:8MV

NR: 042624-1

BIOHARVEST SCIENCES INC. ANNOUNCES GRANT OF RESTRICTED SHARE UNITS AND WARRANTS

VANCOUVER, CANADA, and REHOVOT, ISRAEL, April 26, 2024 -BioHarvest Sciences Inc. ("BioHarvest" or the "Company") (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) announces the grant of 700,000 restricted share units ("RSUs") to a Consultant pursuant to its Equity Incentive Compensation Plan and consulting agreement respectively.

The RSUs are issued at a deemed price of CAD 0.26 per share unit and will be released in increments of 200,000, 250,000, 125,000 and 125,000 RSUs upon the Company achieving various revenue milestones in 2024. In the event of termination of the Consultant's engagement prior to the lapse of twelve (12) months from the Effective Date, any un-vested RSUs shall immediately expire.

In addition, the Company has granted 300,000 warrants to a consultant assigned to assist with the smooth transition of the Company's production capacity to its new 80,000 square foot facility in Yavne, Israel (see news release issued April 16, 2024), and to secure the necessary approvals from local authorities. Each warrant is exercisable into one common share of the Company at a price of CAD 0.26 for a term of two-years from the date of issuance.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

BioHarvest Sciences Inc.

Ilan Sobel, Chief Executive Officer

For further information, please contact:

Dave Ryan, VP Investor Relations & Director Phone: 1 (604) 622-1186

Email: dave@bioharvest.com

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.